Partnerships, Licensing, Investments and M&A Deals andTrends for April 2012 in Pharmaceuticals

• Publication date: May 2012
• Report size: 64 pages

Partnerships, Licensing, Investments and M&A Deals andTrends for April 2012 in Pharmaceuticals Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals andTrends for April 2012 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed in...

Partnerships, Licensing, Investments and M&A Deals andTrends for April 2012 in Pharmaceuticals



Summary



GlobalData's “Partnerships, Licensing, Investments and M&A Deals andTrends for April 2012 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2012. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.



Scope


- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.



Reasons to buy


- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Global Investment Banking Industry

Table of Contents
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 7
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2012 7
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2012 9
2.2.1 Nestle To Acquire Pfizer Nutrition From Pfizer For $11.9 Billion 9
2.2.2 Watson Pharma To Acquire Swiss Drug Maker Actavis Group For Up To $5.9 Billion 9
2.2.3 SXC Health Solutions To Acquire Catalyst Health Solutions For $4.4 Billion 9
2.2.4 Hologic To Acquire Gen-Probe, Diagnostic Test Maker, For $3.7 Billion 10
2.2.5 AstraZeneca To Acquire Ardea Biosciences, Gout Drug Maker, For $1.3 Billion 10
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, April 2012 11
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 12
3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2012 12
3.1.1 Top M&A Deals in April 2012 13
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2011-April 2012 14
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2012 15
3.2.1 Top Equity Offering Deals in April 2012 16
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2011 - April 2012 17
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2012 18
3.3.1 Top PE/VC Deals in April 2012 19
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2012 20
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2012 21
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, November 2011 - April 2012 22
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2011 - April 2012 23
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2012 24
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2012 24
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2011 - April 2012 25
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2012 26
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2012 27
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 28
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), November 2011 - April 2012 29
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 30
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2012 31
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2012 31
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2012 33
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2012 34
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2012 34
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2011 - April 2012 35
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2011 - April 2012 36
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2011 - April 2012 37
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2011 - April 2012 38
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 39
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2012 39
6.1.1 Oncology - Deals of the Month 40
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2012 41
6.2.1 Central Nervous System - Deals of the Month 42
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2012 43
6.3.1 Infectious Diseases - Deals of the Month 44
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2012 45
6.4.1 Immunology - Deals of the Month 46
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, April 2012 47
6.5.1 Metabolic Disorders - Deals of the Month 48
6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, April 2012 49
6.6.1 Gastrointestinal - Deals of the Month 50
6.7 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2012 51
6.7.1 Cardiovascular - Deals of the Month 52
7 Deal Summary by Geography 53
7.1 Pharmaceuticals & Healthcare, North America Deals, April 2012 53
7.1.1 North America - Deals of the Month 54
7.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2012 55
7.2.1 Europe - Deals of the Month 56
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2012 57
7.3.1 Asia-Pacific - Deals of the Month 58
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2012 59
7.4.1 Rest of the World - Deals of the Month 60
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 61
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2011 - April 2012 61
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2011 - April 2012 62
9 Further Information 63
9.1 Methodology 63
9.2 About GlobalData 63
9.3 Contact Us 64
9.4 Disclosure information 64
9.5 Disclaimer 64
List of Tables

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 8
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2012 9
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2012 11
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2012 13
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2011 - April 2012 14
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 15
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2012 16
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 17
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 18
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2012 19
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2011 - April 2012 20
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2012 21
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 22
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2011 - April 2012 23
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 24
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 25
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 26
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2012 27
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 28
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2011 - April 2012 29
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2011 - April 2012 30
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 32
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 33
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, April 2012 34
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2012 34
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), November 2011 - April 2012 35
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2012 36
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2011 - April 2012 37
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2012 38
Table 31: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 40
Table 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 41
Table 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 43
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 45
Table 35: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 47
Table 36: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 49
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 51
Table 38: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 54
Table 39: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 55
Table 40: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 57
Table 41: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 59
Table 42: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 61
Table 43: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 62
List of Figures

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 7
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),April 2012 11
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 12
Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2011 - April 2012 14
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 15
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 17
Figure 7: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 18
Figure 8: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2011 - April 2012 20
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), April 2012 21
Figure 10: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 22
Figure 11: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 24
Figure 12: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 25
Figure 13: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 26
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 28
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2011 - April 2012 29
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 30
Figure 17: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 31
Figure 18: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 33
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 35
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 - April 2012 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), November 2011 - April 2012 37
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2012 38
Figure 23: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 39
Figure 24: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 41
Figure 25: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 43
Figure 26: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 45
Figure 27: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 47
Figure 28: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 49
Figure 29: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 51
Figure 30: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 53
Figure 31: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 55
Figure 32: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 57
Figure 33: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 59
Figure 34: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 61
Figure 35: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2011 - April 2012 62

Investment Banking in World

Fiji Total Government Debt, Us$bn

• $ 250
• Industry data
• January 2013

Yearly, From 1992 To 2022
By Business Monitor International
Source: World Bank, BMI

• Industries : Investment Banking
• Countries : Fiji, World

Fiji Total Government Debt, Us$, % Change Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 1993 To 2022
By Business Monitor International
Source: World Bank, BMI

• Industries : Investment Banking
• Countries : Fiji, World

Fiji Total Government Debt, Eurbn

• $ 250
• Industry data
• January 2013

Yearly, From 1992 To 2022
By Business Monitor International
Source: World Bank, BMI

• Industries : Investment Banking
• Countries : Fiji, World

Fiji Total Government Debt, Eurbn, % Change Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 1993 To 2022
By Business Monitor International
Source: World Bank, BMI

• Industries : Investment Banking
• Countries : Fiji, World

Fiji Total Government Debt, % Of Gdp

• $ 250
• Industry data
• January 2013

Yearly, From 1992 To 2022
By Business Monitor International
Source: World Bank, BMI

• Industries : Investment Banking
• Countries : Fiji, World